Atazanavir

Major

Atazanavir Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Atazanavir Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Atazanavir Dabigatran Pradaxa® Increased dabigatran etexilate exposure and an increased risk of bleeding Details Atazanavir Dabigatran Etexilate Increased dabigatran etexilate exposure and an increased risk of bleeding Details Atazanavir Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Atazanavir Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Atazanavir Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Atazanavir Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Atazanavir Dexamethasone Injection Decadron Reduced atazanavir exposure, reduced efficacy of atazanavir, increased dexAMETHasone exposure and increased risk of dexAMETHasone-... Details Atazanavir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced atazanavir exposure, reduced efficacy of atazanavir, increased dexAMETHasone exposure and increased risk of dexAMETHasone-... Details Atazanavir Dexlansoprazole Dexilant Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Didanosine Videx® Reduced solubility and exposure to atazanavir with the didanosine buffered formulation and reduced didanosine exposure with enteri... Details Atazanavir Disopyramide Norpace Increased antiarrhythmic exposure and an increased risk of QT interval prolongation Details Atazanavir Docetaxel Beizray An increased risk of DOCEtaxel exposure Details Atazanavir Docetaxel Injection Beizray An increased risk of DOCEtaxel exposure Details Atazanavir Dofetilide Tikosyn An increased risk of QT interval prolongation Details Atazanavir Dolasetron Anzemet An increased risk of QT interval prolongation Details Atazanavir Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Atazanavir Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Atazanavir Edoxaban Savaysa Increased edoxaban exposure and an increased risk of bleeding Details Atazanavir Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Atazanavir Eluxadoline Viberzi Increased eluxadoline exposure Details Atazanavir Entrectinib Rozlytrek Increased entrectinib exposure, an increased frequency or severity of adverse reactions including increased risk of cardiac arrhyt... Details Atazanavir Eribulin Injection Halaven An increased risk of QT interval prolongation Details Atazanavir Esomeprazole Nexium Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Esomeprazole Injection Nexium Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Famotidine Calmicid Reduced atazanavir exposure and an increased risk of QT interval prolongation Details Atazanavir Famotidine Injection Calmicid Reduced atazanavir exposure and an increased risk of QT interval prolongation Details Atazanavir Felbamate Felbatol An increased risk of QT interval prolongation Details Atazanavir Felodipine Plendil® An increased calcium channel blocker exposure Details Atazanavir Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Atazanavir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Atazanavir Flecainide Tambocor® Increased antiarrhythmic exposure and an increased risk of QT interval prolongation Details Atazanavir Fluvastatin Lescol Increased HMG-CoA reductase inhibitor exposure Details Atazanavir Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Atazanavir Fostamatinib Tavalisse Increased fostamatinib active metabolite (R406) exposure and an increased risk of fostamatinib-related adverse effects (eg., hepat... Details Atazanavir Fostemsavir Rukobia Increased risk of torsade de pointes Details Atazanavir Galantamine Razadyne An increased risk of QT interval prolongation Details Atazanavir Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Atazanavir Gemifloxacin Factive An increased risk of QT interval prolongation Details